Bridging the translational innovation gap through good biomarker practice

Nature Reviews Drug Discovery 16, 587 (2017). doi:10.1038/nrd.2017.72 Authors: Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders & Anton Ussi Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Comment Source Type: research